Literature DB >> 28825867

Adjuvants for allergy immunotherapeutics.

Carlos Gamazo1, Carmen D'Amelio2, Gabriel Gastaminza3, Marta Ferrer4, Juan M Irache5.   

Abstract

Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response. This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least 2 major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies. This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays.

Entities:  

Keywords:  Anaphylaxis; adjuvant; allergy; immunotherapy; nanoparticle

Mesh:

Substances:

Year:  2017        PMID: 28825867      PMCID: PMC5647973          DOI: 10.1080/21645515.2017.1348447

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  110 in total

1.  Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres.

Authors:  S Pecquet; E Leo; R Fritsché; A Pfeifer; P Couvreur; E Fattal
Journal:  Vaccine       Date:  2000-01-18       Impact factor: 3.641

2.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

3.  Corrigendum to "Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects" [J. Autoimmun. 47C (2013) 1-16].

Authors:  Carlo Perricone; Serena Colafrancesco; Roei D Mazor; Alessandra Soriano; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  J Autoimmun       Date:  2016-06-03       Impact factor: 7.094

Review 4.  Sublingual or subcutaneous immunotherapy for allergic rhinitis?

Authors:  Stephen R Durham; Martin Penagos
Journal:  J Allergy Clin Immunol       Date:  2016-02       Impact factor: 10.793

5.  Administration of a probiotic with peanut oral immunotherapy: A randomized trial.

Authors:  Mimi L K Tang; Anne-Louise Ponsonby; Francesca Orsini; Dean Tey; Marnie Robinson; Ee Lyn Su; Paul Licciardi; Wesley Burks; Susan Donath
Journal:  J Allergy Clin Immunol       Date:  2015-01-13       Impact factor: 10.793

6.  Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells.

Authors:  L K Wilcock; J N Francis; S R Durham
Journal:  Clin Exp Allergy       Date:  2004-09       Impact factor: 5.018

7.  Immunogenicity of peanut proteins containing poly(anhydride) nanoparticles.

Authors:  Juliana De S Rebouças; Juan M Irache; Ana I Camacho; Gabriel Gastaminza; María L Sanz; Marta Ferrer; Carlos Gamazo
Journal:  Clin Vaccine Immunol       Date:  2014-06-04

8.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.

Authors:  Alain Didier; Hans-Jörgen Malling; Margitta Worm; Friedrich Horak; Siegfried Jäger; Armelle Montagut; Claude André; Olivier de Beaumont; Michel Melac
Journal:  J Allergy Clin Immunol       Date:  2007-11-01       Impact factor: 10.793

9.  Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice.

Authors:  Claudia Petrarca; Emanuela Clemente; Valentina Amato; Alessia Gatta; Sara Cortese; Alessia Lamolinara; Cosmo Rossi; Stefania Zanotta; Gianni Mistrello; Roberto Paganelli; Mario Di Gioacchino
Journal:  Clin Mol Allergy       Date:  2016-08-05

Review 10.  New approaches to transcutaneous immunotherapy: targeting dendritic cells with novel allergen conjugates.

Authors:  Richard Weiss; Sandra Scheiblhofer; Yoan Machado; Josef Thalhamer
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-12
View more
  5 in total

Review 1.  Phage therapy in allergic disorders?

Authors:  Andrzej Górski; Ewa Jończyk-Matysiak; Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Beata Weber-Dąbrowska; Jan Borysowski
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-23

2.  Broad perspectives of allergen specific immunotherapy.

Authors:  Wayne Robert Thomas
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 3.  Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease.

Authors:  Isabella Anna Joubert; Mark Geppert; Litty Johnson; Robert Mills-Goodlet; Sara Michelini; Evgeniia Korotchenko; Albert Duschl; Richard Weiss; Jutta Horejs-Höck; Martin Himly
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 4.  Engineered Nanomaterials and Type I Allergic Hypersensitivity Reactions.

Authors:  Nasser B Alsaleh; Jared M Brown
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

5.  Protection Conferred by Drinking Water Administration of a Nanoparticle-Based Vaccine against Salmonella Enteritidis in Hens.

Authors:  Javier Ochoa-Repáraz; Eduard Sebastià; Marta Sitjà; Ibai Tamayo; Juan Manuel Irache; Carlos Gamazo
Journal:  Vaccines (Basel)       Date:  2021-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.